Remdesivir maker Gilead Sciences sees 10% drop in second-quarter sales as demand for non-coronavirus drugs falls

Gilead Sciences' sales fell 10% in the second quarter from a year earlier as the coronavirus pandemic weakened demand for some of its drugs, including some of its core hepatitis treatments.